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Abstract
Optimal vasopressor support during resuscitation should theoreti-
cally enhance aortic diastolic and coronary perfusion pressure as
well as coronary and cerebral blood flow/oxygen delivery without
increasing cellular oxygen demand. Intravenous vasopressor support,
using 1 mg doses of epinephrine every 5 minutes in adults or vaso-
pressin 40 IU, is recommended by American Heart Association
Advanced Cardiac Life Support Guidelines to maximize oxygen
delivery to the heart and brain and increase cellular high energy
phosphate levels. Vasopressin offers theoretical advantages over
epinephrine in that it does not increase myocardial oxygen demand
significantly and its receptors are relatively unaffected by acidosis.
However, unlike epinephrine, it is not a myocardial stimulant.
Despite these differences in physiologic actions, two large
randomized clinical trials yielded virtually identical overall survival to
hospital discharge when these agents were compared during in-
hospital or out-of-hospital resuscitation in Canada and Europe,
respectively. More recent clinical and experimental evidence
suggests that a combination of vasopressin and epinephrine used
during resuscitation can improve hemodynamics and perhaps
survival. The verdict on a combination vasopressor strategy may
soon come from a large (>2,000 patients) prospective clinical trial
that is underway in France to clarify the role of combination
vasopressin/epinephrine therapy in out-of-hospital resuscitation.
In this issue of Critical Care, Stroumpoulis and coworkers [1]
reported that a combination of vasopressin and epinephrine
improve hemodynamics and return of spontaneous circulation
(ROSC) in an experimental cardiac arrest model. Approxi-
mately 400,000 to 460,000 cardiac arrests occur out of the
hospital each year in the USA [2]. Despite major advances in
resuscitation science, overall survival from out-of-hospital
cardiac arrest remains poor, averaging only 5% to 8% in
most communities [3]. The patient’s initial cardiac rhythm is a
principal determinant of resuscitation survival and neurologic
outcome. A ventricular tachyarrhythmia (ventricular tachy-
cardia or fibrillation) is the triggering event in up to 80% of
cases and has the most favorable prognosis if it is treated
promptly by defibrillation [4]. Approximately 25% of out-of-
hospital cardiac arrest survivors require drug therapy for
restoration of spontaneous circulation [5]. However, if prompt
defibrillation cannot be performed and/or is unsuccessful and
the resuscitation team must administer advanced life support
drugs, the odds of survival to hospital discharge are under
10% [6,7].
Weisfeldt and Becker [8] proposed a three-phase model of
resuscitation from cardiac arrest based on the changing
physiologic needs of the patient: electrical, hemodynamic,
and metabolic. For the first few minutes after the onset of
ventricular fibrillation (‘electrical phase’), defibrillation may be
all that is needed for successful resuscitation because the
myocardial cells are still relatively rich in ATP. After 3 to 4
minutes, depletion of myocardial ATP diminishes the heart’s
ability to resume effective contractions after defibrillation.
Attempts at defibrillation during this period are often un-
successful or result in asystole or pulseless electrical activity.
A brief period of effective cardiopulmonary resuscitation
before defibrillation during this second ‘hemodynamic phase’
can boost myocardial ATP levels, increasing the likelihood of
ROSC after defibrillation. Intravenous vasopressor support,
using 1 mg doses of epinephrine every 5 minutes in adults or
vasopressin 40 IU, is recommended by American Heart
Association Advanced Cardiac Life Support Guidelines to
maximize oxygen delivery to the heart and brain and increase
cellular ATP [9]. If spontaneous circulation is not restored for
8 to 9 minutes, then a cascade of cellular metabolic events
usually leads to irreversible end-organ injury (including anoxic
brain damage and postresuscitation myocardial dysfunction).
It is believed that reperfusion protection strategies mitigate
cellular damages during this third ‘metabolic phase’.
Optimal vasopressor support during resuscitation should
theoretically enhance aortic diastolic and coronary perfusion
pressure as well as coronary and cerebral blood flow/oxygen
delivery without increasing cellular oxygen demand. The
principal hypothesis to explain why ‘high dose epinephrine’,
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which looked promising in animal models, did not improve
survival in clinical resuscitation trials is that the increased
coronary perfusion pressure did not increase myocardial
oxygen delivery (the majority of adult cardiac arrest victims,
unlike most experimental animal models, have significant
coronary artery narrowing) sufficiently to offset the increased
myocardial oxygen demand caused by epinephrine’s β-
adrenergic effects [7].
Vasopressin offers theoretical advantages over epinephrine in
that it does not increase myocardial oxygen demand signifi-
cantly and its receptors are relatively unaffected by acidosis.
However, unlike epinephrine, it is not a myocardial stimulant.
Despite these differences in physiologic action, two large
randomized clinical trials yielded virtually identical overall
survival to hospital discharge when these agents were
compared during in-hospital [10] and out-of-hospital [6]
resuscitation in Canada and Europe, respectively. In the
European study, survival to discharge was better with use of
vasopressin than with epinephrine for the subgroup of
patients in whom asystole was the initial rhythm.
Stroumpoulis and coworkers [1] found that a combination of
vasopressin and epinephrine resulted in higher aortic
diastolic and coronary perfusion pressures, as well as better
ROSC, compared with that achieved with epinephrine alone
in an 8-minute untreated ventricular fibrillation experimental
model in large piglets. This is not a new finding, but it adds
further evidence alongside the results of prior animal studies
that showed that this combination improves survival [11-13].
There is also clinical evidence supporting use of a vaso-
pressin/epinephrine ‘combination’ (usually in the form of
sequential or alternating doses of the two drugs) during
resuscitation [6,14-16]. The best evidence to date comes
from the out-of-hospital comparison of epinephrine versus
vasopressin reported by Wenzel and coworkers [6], which
showed no difference in survival between treatment groups.
However, there was better survival in the group of patients
who received two blinded experimental doses of vasopressin
followed by unlabelled epinephrine than in patients who
received just repeated doses of epinephrine.
The 2005 American Heart Association Guidelines on Cardio-
pulmonary Resuscitation and Emergency Cardiovascular
Care [17] recommend epinephrine (1 mg intravenously every
3 to 5 minutes) and state that ‘one dose of vasopressin may
replace either the first or second dose of epinephrine’. The
2005 European Resuscitation Council Guidelines for
Resuscitation [18] conclude that epinephrine, ‘… has been
the standard vasopressor in cardiac arrest. There is insuffi-
cient evidence to support or refute the use of vasopressin as
an alternative to, or in combination with [epinephrine].’
However, based on the mounting clinical and experimental
evidence, Wenzel and Lindner [14] recently suggested that
clinicians consider alternating epinephrine 1 mg intravenously
with vasopressin 40 IU every 3 to 5 minutes. The verdict on a
combination vasopressor strategy may come soon from a
large (>2,000 patients) prospective clinical trial that is
underway in France to clarify the role of combination vaso-
pressin/epinephrine therapy in out-of-hospital resuscitation.
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